VERA
Vera Therapeutics, Inc.
There isn't enough reported data to score VERA yet.
VERA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VERA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
VERA PE Valuation
VERA has no meaningful PE right now: it lost money over the past year.
VERA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VERA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
VERA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.90 | -$1.91 |
| Q2 2026 | -$5.86 | -$2.28 |
| Q1 2026 | -$5.54 | -$2.54 |
| Q4 2025 | -$4.66 | -$1.91 |
| Q3 2025 | -$3.99 | -$1.42 |
| Q2 2025 | -$3.58 | -$1.41 |
| Q1 2025 | -$3.00 | -$0.99 |
| Q4 2024 | -$2.75 | -$0.50 |
VERA lost $5.90 per share over the past year, a bigger loss than the year before.
VERA Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -931% | N/A |
VERA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$99.2M | -$37.1M |
| Q2 2026 | -$100.3M | -$45.2M |
| Q1 2026 | -$106.5M | -$51.9M |
| Q4 2025 | -$70.1M | -$30.3M |
| Q3 2025 | -$62M | -$24.9M |
| Q1 2025 | -$54.6M | -$20.8M |
| Q4 2024 | -$39.8M | -$14.6M |
| Q3 2024 | -$37.1M | -$14.2M |
VERA has burned cash in almost every quarter: −$376M over the past year, against −$211M the year before.
VERA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +289K shares |
| 1 year | +13% | +8.3M shares |
| 3 years | +63% | +27.8M shares |
| 5 years | +587% | +61.6M shares |
| Available history | +1669% | +68.1M shares |
VERA has 72M diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | — |
| Q4 2020 | — |
| Q3 2020 | $61,000 |
| Q2 2020 | — |
| Q1 2020 | — |
VERA Net Leverage
VERA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VERA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 33.1 | Neutral |
VERA's weekly RSI is 40 (neutral) and its Stochastic is 33 (neutral).
VERA PE vs Healthcare Sector
VERA has no meaningful PE right now: it lost money over the past year.
VERA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 2.6% below |
| 20 week MA | $33.2 | 12% below |
| 50 week MA | $38.3 | 24% below |
| 100 week MA | $32.6 | 11% below |
| 200 week MA | $29.2 | 0.4% below |
VERA is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
VERA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.5 | $22.8 | +99% |
| 2022 | $22.8 | $19.9 | -13% |
| 2023 | $19.9 | $15.4 | -23% |
| 2024 | $15.4 | $41.4 | +169% |
| 2025 | $41.4 | $53.6 | +29% |
| 2026 YTD | $53.6 | $29.0 | -46% |
VERA is down 46% so far in 2026, after finishing higher in three of the previous five years.